EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Finerenone in Type 1 Diabetes and Chronic Kidney Disease

Hiddo J L Heerspink iD, Andreas L Birkenfeld, David Z I Cherney, Helen M Colhoun, Per-Henrik Groop, Linong Ji iD, Niels Jongs, Chantal Mathieu, Richard E Pratley, Sylvia E Rosas, Peter Rossing iD, Jay S Skyler und 8 weitere

New England Journal of Medicine · 05.03.2026 · 394 (10) · 947-957

DOI: 10.1056/nejmoa2512854 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 05.03.2026. Verfasst von Hiddo J L Heerspink und 19 weiteren Autor:innen. Beteiligte Einrichtung: George Institute for Global Health, University of New South Wales, Sydney. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetic Nephropathies, Naphthyridines, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetic NephropathiesNaphthyridinesRenal Insufficiency, ChronicAdultAgedFemaleHumansMaleMiddle AgedAlbuminuriaAngiotensin-Converting Enzyme InhibitorsCreatinineDouble-Blind MethodGlomerular Filtration RateHyperkalemiaMineralocorticoid Receptor AntagonistsDrug Therapy, CombinationTreatment OutcomeProspective StudiesPotassiumFollow-Up StudiesAdministration, Oral

Substanzen

Angiotensin-Converting Enzyme InhibitorsCreatininefinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesPotassium

Autor:innen und Institutionen

  • George Institute for Global Health, University of New South Wales, Sydney.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany.
  • German Center for Diabetes Research, Neuherberg, Germany.
  • Internal Medicine IV, Department of Endocrinology, Diabetology, and Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Division of Nephrology, University Health Network, Toronto General Hospital, University of Toronto, Toronto.

ORCID-Profile: Hiddo J L Heerspink, Linong Ji, Peter Rossing, Katherine R Tuttle

Förderung

  • Bayer

Zitieren

APA

Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Groop, P. H., Ji, L., Jongs, N., Mathieu, C., Pratley, R. E., Rosas, S. E., Rossing, P., Skyler, J. S., Tuttle, K. R., Lawatscheck, R., Brinker, M., Scheerer, M. F., Russell, J., Schloemer, P., McGill, J. B., & FINE-ONE Investigators (2026). Finerenone in Type 1 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 394(10), 947-957. https://doi.org/10.1056/nejmoa2512854

Vancouver

Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L, et al. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. New England Journal of Medicine. 2026;394(10):947-957. doi:10.1056/nejmoa2512854

BibTeX
@article{Heerspink2026,
  author = {Heerspink, Hiddo J L and Birkenfeld, Andreas L and Cherney, David Z I and Colhoun, Helen M and Groop, Per-Henrik and Ji, Linong and Jongs, Niels and Mathieu, Chantal and Pratley, Richard E and Rosas, Sylvia E and Rossing, Peter and Skyler, Jay S and Tuttle, Katherine R and Lawatscheck, Robert and Brinker, Meike and Scheerer, Markus F and Russell, Julie and Schloemer, Patrick and McGill, Janet B and FINE-ONE Investigators, FINE-ONE Investigators},
  title = {Finerenone in Type 1 Diabetes and Chronic Kidney Disease},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {10},
  pages = {947--957},
  doi = {10.1056/nejmoa2512854}
}
Kostenlos starten →